AISLING CAPITAL III LP

CIK 00014447178 companiesNEW YORK, NY

SEC Profile

Transactions

Companies

Filings

CIK

0001444717

Recent Transactions

50 trades

Sale
Loxo Oncology, Inc.
Common Stock
2018-07-10$179.43/sh−1,400,000→ 2,038,920 total
Sale
Loxo Oncology, Inc.
Common Stock
2017-12-19$80.50/sh−250,000→ 3,438,920 total
Sale
Loxo Oncology, Inc.
Common Stock
2017-11-22$75.00/sh−500,000→ 3,688,920 total
Purchase
Loxo Oncology, Inc.
Common Stock
2017-01-10$31.00/sh+160,000→ 4,188,920 total
Conversion
Syros Pharmaceuticals, Inc.
Series B Preferred Stock
2016-07-06−1,907,122→ 0 total
Purchase
Syros Pharmaceuticals, Inc.
Common Stock
2016-07-06$12.50/sh+400,000→ 908,565 total
Conversion
Syros Pharmaceuticals, Inc.
Common Stock
2016-07-06+508,565→ 508,565 total
Other
AGILE THERAPEUTICS INC
Common Stock
2016-06-02−400,000→ 2,583,797 total
Purchase
Loxo Oncology, Inc.
Common Stock
2016-05-17$21.50/sh+232,558→ 4,028,920 total
Purchase
Loxo Oncology, Inc.
Common Stock
2015-12-11$27.50/sh+200→ 3,796,362 total
Purchase
T2 Biosystems, Inc.
Common Stock
2015-12-09$9.75/sh+307,692→ 2,830,992 total
Purchase
Loxo Oncology, Inc.
Common Stock
2015-11-17$26.50/sh+265,000→ 3,796,182 total
Purchase
Loxo Oncology, Inc.
Common Stock
2015-11-13$27.47/sh+1,955→ 3,531,182 total
Purchase
Loxo Oncology, Inc.
Common Stock
2015-11-12$27.65/sh+76,714→ 3,529,207 total
Purchase
Aravive, Inc.
Common Stock
2015-01-27$17.25/sh+145,000→ 2,139,568 total
Purchase
AGILE THERAPEUTICS INC
Common Stock
2015-01-23$5.85/sh+811,966→ 2,983,797 total
Conversion
T2 Biosystems, Inc.
Series D Convertible Preferred Stock
2014-08-12−2,967,033→ 0 total
Conversion
T2 Biosystems, Inc.
Series E Convertible Preferred Stock
2014-08-12−549,851→ 0 total
Conversion
T2 Biosystems, Inc.
Common Stock
2014-08-12+2,068,755→ 2,068,755 total
Purchase
T2 Biosystems, Inc.
Common Stock
2014-08-12$11.00/sh+454,545→ 2,523,300 total
Conversion
Loxo Oncology, Inc.
Series B Convertible Preferred Stock
2014-08-06−506,960→ 0 total
Conversion
Loxo Oncology, Inc.
Common Stock
2014-08-06+2,850,709→ 3,039,416 total
Conversion
Loxo Oncology, Inc.
Series A Convertible Preferred Stock
2014-08-06−2,343,749→ 0 total
Purchase
Loxo Oncology, Inc.
Common Stock
2014-08-06$13.00/sh+413,077→ 3,452,493 total
Conversion
Aravive, Inc.
Series E Convertible Preferred Stock
2014-03-26−5,486,820→ 0 total
Conversion
Aravive, Inc.
Common Stock
2014-03-26+35,104→ 35,104 total
Conversion
Aravive, Inc.
Series B Convertible Preferred Stock
2014-03-26−403,704→ 0 total
Conversion
Aravive, Inc.
Common Stock
2014-03-26+128,695→ 1,400,514 total
Conversion
Aravive, Inc.
Common Stock
2014-03-26+56,939→ 1,457,453 total
Conversion
Aravive, Inc.
Common Stock
2014-03-26+1,236,715→ 1,271,819 total
Conversion
Aravive, Inc.
Common Stock
2014-03-26+477,115→ 1,934,568 total
Conversion
Aravive, Inc.
Series C Convertible Preferred Stock
2014-03-26−14,222,222→ 0 total
Conversion
Aravive, Inc.
Series D-1 Convertible Preferred Stock
2014-03-26−1,479,993→ 0 total
Conversion
Aravive, Inc.
Series D-2 Convertible Preferred Stock
2014-03-26−654,796→ 0 total
Purchase
Aravive, Inc.
Common Stock
2014-03-26$21.00/sh+60,000→ 1,994,568 total
Sale
Durata Therapeutics, Inc.
Common Stock
2014-03-21$15.57/sh−2,649→ 3,030,175 total
Sale
Durata Therapeutics, Inc.
Common Stock
2014-03-20$15.74/sh−98,000→ 3,032,824 total
Other
Zeltiq Aesthetics Inc
Common Stock
2014-01-23+4,697→ 4,697 total
Other
Zeltiq Aesthetics Inc
Common Stock
2014-01-23−4,715→ 0 total
Other
Zeltiq Aesthetics Inc
Common Stock
2014-01-23−994,305→ 2,597,742 total
Other
Zeltiq Aesthetics Inc
Common Stock
2014-01-23+1,152→ 1,152 total
Other
Zeltiq Aesthetics Inc
Common Stock
2014-01-23+2,398→ 2,398 total
Conversion
ASENSUS SURGICAL, INC.
Common Stock
2013-12-06+12,401,764→ 36,490,260 total
Sale
Zeltiq Aesthetics Inc
Common Stock
2013-11-14$12.22/sh−575,000→ 3,597,742 total
Purchase
ASENSUS SURGICAL, INC.
Series B Preferred Stock
2013-09-03$4.00/sh+1,240,176.4→ 1,240,176.4 total
Conversion
Durata Therapeutics, Inc.
Common Stock
2012-07-24+2,019,713→ 2,019,713 total
Conversion
Durata Therapeutics, Inc.
Series A Preferred Stock
2012-07-24−16,157,707→ 0 total
Purchase
Durata Therapeutics, Inc.
Common Stock
2012-07-24$9.00/sh+1,111,111→ 3,130,824 total
Conversion
ASENSUS SURGICAL, INC.
Series B Preferred Stock
2012-07-24−1,240,176.4→ 0 total
Purchase
Zeltiq Aesthetics Inc
Common Stock
2011-10-24$13.00/sh+769,231→ 4,172,742 total

AISLING CAPITAL III LP

Recent Transactions

Companies

Recent Filings

Address